Sonya Youngju Park1, Eun Kyoung Choi2, Jin Kyoung Oh3, Joo Hyun Oh1, Ie Ryung Yoo1, Yong An Chung4. 1. Department of Radiology, Seoul St. Mary's Hospital, Seoul, Korea. 2. Department of Radiology, Incheon St. Mary's Hospital, Seoul, Korea. 3. Department of Radiology, Incheon St. Mary's Hospital, Seoul, Korea. mirriam@catholic.ac.kr. 4. Department of Radiology, Incheon St. Mary's Hospital, Seoul, Korea. nm@catholic.ac.kr.
Abstract
PURPOSE: The purpose of this study was to compare the survival of patients with and without BAT activity on FDG PET/CT. METHODS: PET/CT exams from 3937 breast cancer patients were retrospectively reviewed for bilateral symmetric elongated FDG activity in the neck and chest, typical of BAT activation. A control group of age-matched (± 1 year) breast cancer patients who underwent PET/CT the same week was also enrolled for comparison. Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) for BAT positive patients and the control group were calculated. Further sub-analysis was performed to account for the hormonal changes associated with menopause. RESULTS: 2.0% (80/3937) of the breast cancer patients who underwent PET/CT demonstrated BAT activation, and 80 additional patients were analyzed for comparison as the group without BAT activity. Mean follow-up was 76 months (range 1-225 months). There were 4 recurrences in the BAT group, compared to 12 in the control. The mean PFS for the BAT group was 127 months, which was significantly lower than the mean PFS of 180 months in the control (p = 0.047). Sub-analysis of premenopausal women again showed longer PFS for the BAT group (129 vs. 196 months, p = 0.095) while no difference was found in postmenopausal women (mean 102 vs. 135 months, p = 0.360). Presence of BAT activity was also a significant predictor variable for PFS on Cox regression. CONCLUSION: Patients with BAT activity showed longer progression-free survival than those without, emphasizing the need for further evaluation of its role in metabolism, treatment response, tumor microenvironment and long-term prognosis.
PURPOSE: The purpose of this study was to compare the survival of patients with and without BAT activity on FDG PET/CT. METHODS: PET/CT exams from 3937 breast cancer patients were retrospectively reviewed for bilateral symmetric elongated FDG activity in the neck and chest, typical of BAT activation. A control group of age-matched (± 1 year) breast cancer patients who underwent PET/CT the same week was also enrolled for comparison. Kaplan-Meier curves of progression-free survival (PFS) and overall survival (OS) for BAT positive patients and the control group were calculated. Further sub-analysis was performed to account for the hormonal changes associated with menopause. RESULTS: 2.0% (80/3937) of the breast cancer patients who underwent PET/CT demonstrated BAT activation, and 80 additional patients were analyzed for comparison as the group without BAT activity. Mean follow-up was 76 months (range 1-225 months). There were 4 recurrences in the BAT group, compared to 12 in the control. The mean PFS for the BAT group was 127 months, which was significantly lower than the mean PFS of 180 months in the control (p = 0.047). Sub-analysis of premenopausal women again showed longer PFS for the BAT group (129 vs. 196 months, p = 0.095) while no difference was found in postmenopausal women (mean 102 vs. 135 months, p = 0.360). Presence of BAT activity was also a significant predictor variable for PFS on Cox regression. CONCLUSION: Patients with BAT activity showed longer progression-free survival than those without, emphasizing the need for further evaluation of its role in metabolism, treatment response, tumor microenvironment and long-term prognosis.
Authors: C Rousseau; E Bourbouloux; L Campion; N Fleury; B Bridji; J F Chatal; I Resche; M Campone Journal: Eur J Nucl Med Mol Imaging Date: 2006-04-05 Impact factor: 9.236
Authors: Leontine E H Bakker; Mariëtte R Boon; Rianne A D van der Linden; Lenka Pereira Arias-Bouda; Jan B van Klinken; Frits Smit; Hein J Verberne; J Wouter Jukema; Jouke T Tamsma; Louis M Havekes; Wouter D van Marken Lichtenbelt; Ingrid M Jazet; Patrick C N Rensen Journal: Lancet Diabetes Endocrinol Date: 2013-11-12 Impact factor: 32.069